| studies for . . .
|
| CLINICAL FEATURES | STUDY (for more information, click on the study name, if highlighted) | CONTACT |
| Healthy volunteers without a movement disorder (needed as controls for other studies) | ||
| normal, spouse of Parkinson's disease patient | PD genetics | L. Good |
| any adult with no neurological or psychiatric illness or history of substance abuse | high-resolution MRI study | J. Hartlein |
| effects of levodopa on memory and attention | T. Hershey | |
| Parkinson's disease | ||
| all patients with PD | PD genetics | L. Good |
| effects of levodopa on memory and attention | T. Hershey | |
| deep brain stimulation patients | = movement kinematics
= functional imaging study (PET) |
A. Loepker |
| patients with diagnosed PD for less than 5 years who do not currently need treatment | to determine the effectiveness of an investigational study
medication (CEP-1347)in slowing disease progression |
P. Deppen |
| PD patients who have responded to L-DOPA (Sinemet) at some point | = MRI measurement of dopamine function (apomorphine fMRI)
= functional imaging of levodopa effects on memory and attention |
J. Hartlein |
| psychosis (hallucinations) in Parkinson's disease | olanzapine | J. Hartlein |
| patients with PD who have never been treated | imaging study of oxidative metabolism | L. McGee-Minnich |
| Tremor | ||
| PD or essential tremor patients who have had deep brain stimulator surgery | = PET study
= kinematic study |
L. McGee-Minnich |
| bilateral essential or Parkinson tremor | bilateral thalamic stimulation | A. Loepker |
| Dystonia | ||
| all dystonia | genetics study | L. Good |
| Huntington's disease | ||
| Patients with HD, or at-risk family members | = clinical evaluation
= imaging study of oxidative metabolism |
P. Cooper
L. McGee-Minnich |